EMAAR

We are the RISK lens. We need to check the concrete breaks (thresholds) with exact figures from the pack. First, define thresholds: - ocf_to_ni < 0.7 (accrual-heavy earnings) - net_debt_to_ebitda > 4 - ebitda_interest_cover < 2 - liquidity.advv_30d_aed_m < 1 (exit risk) -> 1 million AED? Possibly. The pack has liquidity.advv_30d_aed_m: 270.0629, so well above 1. - quarterly_gaps present (unverifiable trend) — check if there are gaps? The pack says indicators.largest_gap_3m_pct: 12.7778, and indicators.pct_no_trade_days_3m: 4.6875. The threshold is "quarterly_gaps present" — Is that a qualitative judgment? Probably if there are missing quarters in the data? Looking at quarterly array: we have periods: 2026-03-31, 2025-12-31 (derived), 2025-09-30, 2025-06-30, 2025-03-31, 2024-12-31 (derived). That covers consecutive quarters. No missing quarters. So no gaps. - dividend cut evident in financial_statements. Check dividends: corporate actions history shows dividends: 2026: 100% cash dividends, 2025: 100%, 2024: 50%, 2023: 25%, 2022: 15%. So increasing, no cut. Now compute the ratios: 1. ocf_to_ni: financial_statements.derived.ocf_to_ni = 1.5. So 1.5 > 0.7, NO break. 2. net_debt_to_ebitda: We need net debt and EBITDA. Net debt = total debt - cash. But we need total debt. From balance sheet: total_liabilities for 2025 annual: 79024.4. But that includes all liabilities. We need interest-bearing debt. The pack doesn't have a separate short-term and long-term debt breakdown. But we have interest_expense: -1028.1 (negative means expense, so 1028.1 absolute). Could approximate debt if we have interest rate, but not given. Alternatively, sometimes debt_to_equity is given: fundamentals.debt_to_equity: 0.1121. That is presumably total debt / equity? But careful: debt_to_equity ratio typically includes only interest-bearing debt. So debt = 0.1121 * equity = 0.1121 * 107676.3 ≈ 12070.4. Then net debt = debt - cash = 12070.4 - 52632.9 = negative, so net debt negative. So net_debt_to_ebitda is negative, so definitely < 4. But to be thorough, compute EBITDA. EBITDA = operating profit + depreciation + amortization. Not directly given. We have operating margin: 45.3847% of revenue? fundamentals.operating_margin = 45.3847. Revenue 49557.3, so operating profit = 0.453847 * 49557.3 ≈ 22492.5. We need D&A. We don't have it. We could approximate EBITDA from OCF? Not really. But if net debt is negative, ratio is negative < 4. So no break. But wait, maybe net debt definition: total debt minus cash? Yes. So no break. 3. ebitda_interest_cover: EBITDA / interest expense. Interest expense = 1028.1. Need EBITDA. If we approximate EBITDA: could be operating profit + D&A. But we don't have D&A. Could use OCF? Not accurate. Alternatively, we might notice that the company has very low debt, so likely high coverage. Even if we assume EBITDA is lower, no indication of distress. The company is profitable. Could we approximate: net margin 35.56%, net income 22325.5, so maybe EBITDA is much higher. Unlikely to be below 2x. But we need exact figure? The pack doesn't provide EBITDA. The break requires a figure. If we can't compute, maybe we can't claim a break. But the instruction says "Score these concrete breaks, each only when the cited figure crosses its threshold". That means we need a cited figure from the pack. For ebitda_interest_cover, there's no direct field. We might not be able to cite it. So we skip unless we can compute from given fields? But the pack doesn't have EBITDA. So we cannot confirm break. So no break. 4. liquidity.advv_30d_aed_m < 1: liquidity.advv_30d_aed_m = 270.0629, so >1. No break. 5. quarterly_gaps: no missing quarters, so no break. 6. dividend cut: no cut, dividends increasing. No break. Thus, 0 breaks. So stance should be BUY (since 0 breaks -> BUY is legitimate risk-lens output when balance sheet clean and cash conversion strong). But the instruction also says: "0 breaks -> your stance follows the evidence like any analyst (BUY is a legitimate risk-lens output when the balance sheet is clean and cash conversion strong)". So we output BUY. Now, we need a point sentence citing a figure. For risk lens, we might say something like "OCF to NI of 1.5 indicates strong cash conversion, and net debt is negative." But we need to cite exact figures. The point is a one-sentence summary. Risk line: "Risk is low with strong cash flow and low leverage." Something like that. Confidence: We need to assess. The breaks are 0, so clean. Any catalyst? There may be news, but no specific dated catalyst inside the 4-week horizon? The horizon ends 2026-08-17. Any catalyst? Looking at recent disclosures: there's one on 2026-06-11 about a masterplan, but that's past. The next results? The last filing was for Q1 2026 on 2026-05-11. Q2 results likely in August? The typical pattern: Q2 results filing dates from history: 2025-08-08, 2025-08-06. So Q2 2026 would be around early August 2026. That falls within the horizon (ending 2026-08-17). So there is a likely catalyst: Q2 2026 earnings release. But is it explicitly stated? Not directly. The pack has "catalysts.filings_12mo": 30, and results_filing_dates_24mo shows dates. The next one after May 2026 would be around August. So we have a potential catalyst. But no specific announcement. The instruction says: "90-100 = multiple independent cited figures align AND a dated catalyst sits inside the horizon". Here, we have multiple clean figures (ocf_to_ni, advv, no gaps, no dividend cut, negative net debt). And a catalyst (Q2 earnings) likely inside horizon. But is "dated" means a specific date mentioned? The pack does not have a specific date for Q2 results. However, from the pattern, it's highly probable. The instruction: "Do not assert a specific dated catalyst... unless it appears in a pack field or a filing_context excerpt". So we cannot say Q2 earnings date unless it's in the pack. The pack has no such announcement. So no dated catalyst explicitly. So confidence might be 70-89 (several aligned figures, no dated catalyst). We have multiple aligned cited figures: ocf_to_ni, advv_30d_aed_m, no gaps, dividend history showing no cut. So confidence 85 maybe. But we need to decide: 70-89 band. Target: We can derive from pack evidence for 4-week horizon. The spot is 11.04. We could consider technicals: it's down recently, but with strong fundamentals, maybe a rebound. But no clear target. We could use a simple valuation: forward PE 5.118, earnings growth strong. But 4-week target is short-term. Maybe we can say "no specific target" and output null? The instruction says: "If you output a target, derive it from pack evidence for the 4-week horizon — do not restate analyst.target_mean". So we can output null if we don't have a basis. However, we might use the recent decline to expect a bounce to some moving average? The spot is 11.04, ma50 is 11.84, ma200 is 12.71. But that's not robust. Since no dated catalyst, we can set target null. So output target: null. Now citations: We need at least 2 for non-HOLD stances. We'll cite ocf_to_ni, liquidity.advv_30d_aed_m, and perhaps dividend cut evidence (corporate actions showing no cut). Also maybe debt_to_equity low. But we should cite the exact fields for our case: ocf_to_ni: 1.5, advv: 270.0629, and maybe corporate_actions.history.0.details showing 100% dividends latest, indicating no cut. Also no gaps: we might cite indicators.largest_gap_3m_pct and pct_no_trade_days_3m but that's not directly "quarterly_gaps". The quarterly array shows consecutive periods; we can cite the quarterly periods to show no gaps. But we'll stick to the clearest ones. So citations: - {"field":"financial_statements.derived.ocf_to_ni","value":1.5} - {"field":"liquidity.advv_30d_aed_m","value":270.0629} - For dividend: corporate_actions.history.0.details is "100% cash dividends" and year 2026, showing no cut relative to previous years? We could also cite fundamentals.dividend_yield or payout_ratio but that's not directly a cut. Better to cite the history: corporate_actions.history.0.details, but we need a value. So we can say "Corporate actions show 100% cash dividends in 2026, up from 100% in 2025, no cut." But the field is a string. So {"field":"corporate_actions.history.0.details","value":"100% cash dividends"} and also .1 etc. But we can just cite that. Also, net debt negative: we can show debt_to_equity = 0.1121 and cash = 52632.9, so net debt negative. But we don't have a direct net debt field. We can cite fundamentals.debt_to_equity and financial_statements.annual.0.cash, but that's two citations. We'll include a few. But the instruction: "citations: list the exact pack fields your case rests on, as DOTTED paths with the value you read". So we list the fields and values. For dividend cut, we can cite the history array. But to show no cut, we might need to compare years. Easiest: we have corporate_actions.history.0.type is "Cash Dividends" and details is "100% cash dividends". That alone doesn't prove no cut, unless we note it's the same or higher than prior. But we can cite multiple: corporate_actions.history.1.details: "100% cash dividends", history.2: "50% cash dividends", so increasing. That would be multiple citations. But at least 2 required. We'll include the ocf and advv ones, and optionally a third. Confidence: 85 seems reasonable. No dated catalyst, but figures align well. Now, point: "OCF/NI at 1.5 signals strong cash conversion, and ADV of AED 270M provides ample liquidity." That includes two figures. Risk: "No balance-sheet stress; low leverage, high liquidity, and no dividend cut." Stance: BUY. Target: null. Now output JSON in order: citations, point, risk, stance, confidence, target. Make sure citations is an array of objects with field and value. Use exact dotted paths. Let's also check if any break might be triggered by a different interpretation of net_debt_to_ebitda. Some might use total liabilities as debt? But that includes payables, etc. Typically net debt is interest-bearing debt minus cash. The pack doesn't give interest-bearing debt separately. So using debt_to_equity seems reasonable. But we can't compute EBITDA anyway without D&A. So we skip. Thus, final output.

We are asked to output a stance on EMAAR from the macro-liquidity lens. The macro-liquidity lens is cross-sectional: the peg and Fed rate are identical for all 61 DFM names, so they can't justify a stance by themselves. A non-HOLD stance must cite which of this name's own figures makes it MORE or LESS exposed to the macro backdrop than the market. Specifically, we should consider: fundamentals.debt_to_equity (rate sensitivity), tv_technicals.beta_1y, liquidity.advv_30d_aed_m (flow sensitivity), sector, peer_context percentiles. Cite macro.fed_funds_rate / macro.vix / macro.yield_curve_2s10s_pct for the backdrop AND the differentiating name-level figure; weigh uae_macro_news where present. We need to output JSON with keys: citations, point, risk, stance, confidence, target. First, gather relevant macro data: - macro.fed_funds_rate: 3.63 (as of 2026-06-01) - macro.vix: 16.73 (as of 2026-07-16) - macro.yield_curve_2s10s_pct: 0.37 (as of 2026-07-17) — slightly positive, still relatively flat but not inverted. Now, for EMAAR specifically: - fundamentals.debt_to_equity: 0.1121 (very low) - tv_technicals.beta_1y: 1.5146 (relatively high) - liquidity.advv_30d_aed_m: 270.0629 (reasonable liquidity, but we need to compare to peers? It's given as absolute. For macro-liquidity lens, we consider flow sensitivity: higher ADV might mean more institutional flow, but we need to interpret. The lens says "flow sensitivity". Possibly higher ADV means more sensitive to macro flows? But actually, high liquidity might make it more resilient to macro shocks. The lens instructions: "liquidity.advv_30d_aed_m (flow sensitivity)" so higher ADV might indicate higher flow sensitivity. But we need to differentiate: is EMAAR's ADV high relative to the market? We have peer_context.median_pe_ttm etc., but not median ADV. So we might use it as an absolute: 270M AED is high for DFM, likely making it more liquid and thus more sensitive to macro-driven flows. - sector: Real Estate — typically sensitive to interest rates via mortgage rates and cost of capital. - peer_context: pe_percentile: 7 (low P/E relative to peers: 5.17 vs median 11.32), div_yield_percentile: 97 (high dividend yield relative to peers: 8.65% vs median 4.55%). Low P/E and high dividend yield might indicate value and defensive characteristics, but from a macro-liquidity perspective, we are considering sensitivity. We need to determine if EMAAR is more or less exposed to the macro conditions than the market. The current macro: Fed funds at 3.63%, yield curve slightly positive (0.37), VIX moderate (16.73). For a real estate company with low debt-to-equity (0.11), it is less sensitive to interest rate changes because it has very little debt. High beta (1.51) suggests it is more volatile than the market, which might make it more sensitive to market swings driven by macro. High liquidity (ADV 270M) might mean it's more prone to foreign flows reacting to macro. Also, high dividend yield might attract income investors when rates are low, but with Fed funds at 3.63%, maybe not as attractive. From the macro-liquidity lens, we need to decide if the macro backdrop (rates, VIX, yield curve) combined with EMAAR's characteristics justifies a BUY, SELL, or HOLD. The backdrop: moderate rates, not too high, VIX not extremely high (16.73 is below average fear). Positive but small yield curve slope. So not a macro stress environment. For a low-debt real estate company, this might actually be favorable because it can borrow cheaply if needed, but it already has low debt. However, high beta might suggest it could underperform if macro turns sour, but current macro isn't sour. Also, the UAE macro news includes some positive developments (Emiratization, Jaywan payment scheme) and some geopolitical noise (Houthis embargo). But none seem directly impactful for EMAAR within four weeks. We need a four-week horizon ending 2026-08-17. Catalysts: recent disclosures include a big masterplan announcement (June 11) but that's already out. Q1 2026 results were May 11, so next earnings likely in August? Looking at history, Q2 results might be filed around August. The last results filing dates show August 2025 around Aug 6-8. So there might be a Q2 2026 filing soon. That could be a catalyst. But the horizon is only until Aug 17, so Q2 results could be disclosed within that window. The "catalysts.filings_12mo": 30 indicates many filings last year, so likely there will be a filing soon. However, no explicit date is given. The instruction says: "Do not assert a specific dated catalyst, a project/tender name, or that a consensus is unanimous unless it appears in a pack field or a filing_context excerpt". We don't have a specific date for the next results filing. The recent_disclosures and results_filing_dates_24mo include patterns: Q1 2026 was May 11, 2026; FY2025 was Feb 12, 2026. So Q2 might be mid-August. We can note that in the point, but we need to cite if there's a specific date? The pack provides catalysts.last_results_filing.date and headline, but no future date. So we might not have a definitive catalyst within the horizon. That affects confidence. We need to decide stance. Let's analyze the macro-liquidity factors: - Debt/equity: 0.1121. This is very low, meaning EMAAR has low leverage and thus low sensitivity to rising rates. In a backdrop where Fed funds is 3.63% (not extremely high, but not low), this is positive because it's less exposed than companies with high debt. So EMAAR is less rate-sensitive than peers. That might support a BUY if macro concerns exist, but macro seems okay. - Beta: 1.5146, meaning it's more volatile than the market. If macro improves, it could outperform; if macro worsens, it could underperform. Current VIX 16.73 is moderate, indicating no extreme fear, but beta amplifies any moves. The yield curve is only slightly positive, which might signal cautious growth. Given the moderate macro, high beta could be a positive if we expect stability, but it's a double-edged sword. - ADV: 270M AED, high. This likely indicates high liquidity and thus higher flow sensitivity. If global macro funds flow into UAE, EMAAR might benefit, but outflows could hurt. No strong signal in either direction from current macro flows. - Sector: Real Estate is cyclical and sensitive to interest rates, but EMAAR's low debt mitigates that. - Peer context: Low P/E percentile (7) means it's undervalued relative to peers; high dividend yield percentile (97) means it's attractive for income. These are more fundamental than macro, but they could mean the stock already reflects macro concerns? Given the low debt, high beta, and moderate macro, I'd lean that EMAAR is well-positioned to withstand moderate macro, but the high beta could cause downside if macro turns. The recent negative returns: ret_1m_pct: -13.2%, vs DFMGI ret_1m_pct: -5.96%, so it underperformed significantly recently. That might be a buying opportunity if macro stabilizes. The RSI is 33.21, approaching oversold. The technicals are bearish (TV recommend all: -0.5576, ma: -0.9333). This might be a contrarian signal for a bounce within 4 weeks? The horizon is short-term. From a pure macro-liquidity lens, the differentiating factor is low debt/equity, which makes it less exposed to the rate environment. That is a positive when rates are at 3.63% (not extremely low). High beta might be a risk, but with VIX moderate, it's not screaming sell. The sector is real estate, which is sensitive, but low debt helps. So overall, the macro-liquidity factors seem to suggest a slight positive bias because of low debt, but the high beta and underperformance might continue if macro doesn't improve. However, we need to see if there is a catalyst in the horizon. The recent news about a $54bn project might be a catalyst if more news comes. But it's not dated inside the horizon. The disclosure on June 11 about the masterplan is already priced in? The stock is down 13% in the past month, so maybe not. Given the evidence, maybe a HOLD is appropriate because the macro backdrop doesn't strongly favor a move in either direction, and the name-specific characteristics are mixed. But the instruction says: "non-HOLD stances need at least 2 citations" and confidence below 40 must be HOLD. If we think stance is BUY or SELL, we need to support with at least 2 cited fields. Let's see if we can justify a BUY with macro and name-specific figures. Potential BUY thesis: Low debt-to-equity (0.1121) implies low sensitivity to Fed rate of 3.63%, so compared to peers, it's less exposed to rate risk. High beta (1.5146) could mean it will bounce harder when macro sentiment improves, and with VIX at 16.73 (moderate), markets might stabilize. But that's speculative. Potential SELL thesis: High beta means it's more sensitive to macro downturns, and with a yield curve near flat (0.37), recession fears could hurt high-beta names. Low debt might not protect if demand falls. But the macro isn't in recession territory. I think it's safer to go HOLD because there's no clear macro catalyst within 4 weeks that would uniquely benefit EMAAR more than the market. The low debt is defensive, but the high beta is aggressive. The recent underperformance and oversold RSI might argue for a bounce, but that's technical, not macro-liquidity. The macro-liquidity lens focuses on debt, beta, liquidity, sector. So we need to output based on that. Let's quantify: Debt/equity extremely low, so rate sensitivity is minimal. Beta high, so market sensitivity high. Which dominates? If we think macro volatility will increase (VIX could spike), high beta would hurt. But VIX is moderate, not predicting spike. The yield curve is slightly positive, not inverted, so no imminent recession signal. Fed funds at 3.63% is not overly restrictive. So macro backdrop is benign. In a benign macro, high beta stocks might do well. But EMAAR just fell 13% in a month, so maybe it's already pricing in macro concerns? The macro-liquidity lens might say that with low debt, it's a BUY in a benign macro environment. However, we must consider that the lens mandates that a non-HOLD stance must cite a name-specific figure that makes it more or less exposed. I can cite low debt/equity making it less exposed to rate risk, which is a positive given the fed funds rate. And high beta making it more exposed to general market moves, which could be positive if market stabilizes. But that's not a clear buy signal. Maybe the stance should be HOLD, confidence maybe 40-50? If we think the evidence is mixed. But let's see if the pack has uae_macro_news that affects the sector. The uae_macro_news include several positive items: Emiratization, Jaywan payment scheme, BRICS transport talks, but also Houthis naval embargo which could be negative for the region. The Houthis news might spike risk perception, but it's not directly UAE. The UAE-focused news are generally positive, so macro for UAE is okay. That might support a slightly positive stance. But the lens says "weigh uae_macro_news where present". That might tilt positive. But to get a BUY with confidence >70, we need multiple independent cited figures aligning and a dated catalyst inside the horizon. We don't have a dated catalyst. The Q2 results might fall inside the horizon (around Aug 6-12 based on history), but it's not explicitly stated. So we can't assert it. That means confidence would be limited to 70-89 at best (several aligned cited figures, no dated catalyst). But if we only have mixed evidence, confidence might be lower. Let's list potential citations for a BUY: 1. Macro: fed_funds_rate at 3.63% - not extremely high, so rate sensitivity not a major headwind. 2. Name-specific: debt_to_equity 0.1121, very low, making EMAAR less exposed to rate increases compared to peers with higher debt. 3. Possibly high beta could mean it will outperform if market recovers, but that's speculative. 4. Peer context: low P/E percentile and high div yield percentile co

We are asked to output a JSON for EMAAR (Emaar Properties PJSC) from a SECTOR specialist perspective, focusing on business economics, growth, margins, leverage, dividend durability. We must reason over the provided pack, cite exact figures, and derive a 4-week stance (ending 2026-08-17). Today is 2026-07-20. Key points to assess: - Revenue and margin trends (multi-year): Revenue growth is strong: annual revenue 2025: 49,557.3m, 2024: 35,504.9m, 2023: 26,749.8m, 2022: 24,925.7m. 2-year CAGR from 2023 to 2025: rev_cagr_2y_pct = 36.1%. NI CAGR: 22.7%. Gross margin: 2025: 54.9%, 2024: 57.4%, 2023: 63.0% — a declining trend in gross margin, but net margin: 2025: 45.0%, 2024: 49.1%, 2023: 55.4% — also declining, though still healthy. Q1 2026: revenue 12,398m, net margin 51.7% (improvement vs. full year 2025's 45.0%). Revenue yoy growth Q1 2026: 22.8%. - Leverage: Debt to equity: 0.1121 (very low). Liabilities to equity: 0.73 (annual 2025). Current ratio: 1.7671. Very low financial risk. Interest expense is modest (1,028m) relative to net income (22,325m) — interest coverage strong. - Dividend durability: Dividend yield 8.65%, payout ratio 44.69% — appears sustainable given earnings. Corporate actions show 100% cash dividends for 2025 and 2026 (ex-dates April). Dividend history shows increasing dividends (15% in 2022, 25% in 2023, 50% in 2024, 100% in 2025 and 2026). This indicates confidence and durable cash flows. OCF to NI ratio: 1.5, strong cash generation. - Peer context: PE percentile 7 (low P/E relative to peers, median 11.32 vs EMAAR 5.17), div yield percentile 97 (very high yield). PB 1.035 vs median 1.35. So undervalued relative to sector on multiples but high dividend yield. - Analyst consensus: Strong buy, target 16.85, implied upside 52.6%. However, our target is for 4-week, not 12-month. Recent EPS revisions: 30d +2.76%, 90d -7.75%. Net up 30d: 1. So recent positive revision. But note the 90d downward revision. Overall, analysts bullish. - Recent news/disclosures: On 2026-06-11, Emaar announced an AED200 billion masterplan (the "most ambitious masterplan ever") in Dubai. This could be a catalyst, but no specific dated catalyst within the 4-week horizon beyond the ongoing sentiment around this revelation. The news is from June, so the market has had some time to digest. Also, there are delays on Creek Tower tender (June 23 news) due to cost issues. These might weigh on sentiment. But the massive new project could drive long-term growth. No upcoming earnings within horizon: last results were Q1 2026 reported 2026-05-11, next likely around August? Actually, historically, Q2 results might be in August: looking at catalysts.results_filing_dates_24mo, we see many dates in August for previous years (e.g., 2025-08-08, 2024-08-12). So Q2 2026 results could be released during the horizon (ending Aug 17). The last results filing for Q1 was May 11, and the next is typically about 3 months later, so early-mid August. There is no explicit date in the pack for next results, but we can infer it might be a catalyst. However, the pack says catalysts.filings_12mo: 30, but no specific upcoming date. The most recent disclosure is June 11. No explicit dated catalyst inside the horizon other than potential Q2 results. But we are not to assert a specific dated catalyst unless it appears in the pack. The pack does not explicitly list an upcoming results date within the horizon, but historical pattern suggests one might occur. However, we must cite only pack fields. So we cannot assume a catalyst. - Technicals: Price 11.04, below both MA50 (11.84) and MA200 (12.71). RSI 14 = 33.21 (near oversold). Down -13.2% in past month, -24.6% 6-month, -26.4% YTD. So significant recent weakness. Relative strength vs DFMGI: -7.9% over 3 months. TV recommend all: -0.5576 (strong sell). So technicals are bearish. - Macro: VIX 16.73 (moderate), Fed funds 3.63%, yield curve slightly positive. Dubai real estate sector news: mostly positive (new projects, no specific negative regulatory news). Houthi embargo might cause regional tension but UAE seems insulated. Now, from SECTOR lens, we look at fundamentals: EMAAR has strong growth, margins are compressing but still high, leverage is low, dividends well covered, and it appears undervalued vs peers. However, price momentum is negative. For a 4-week horizon, the weight on fundamentals might be limited without a catalyst. The recent masterplan announcement could provide some support, but the market has been selling off. The discount to moving averages and RSI near oversold might suggest a bounce, but that's technical, not sector fundamental. We need to output stance: BUY, HOLD, or SELL; confidence 0-100. The instructions: "ground your case in the multi-year financial_statements trends (revenue/margin trajectory), not just TTM snapshots". We have multi-year data showing strong revenue growth (CAGR 36.1%), but margin compression. "weigh sector_news items where present" - there are sector news items, but they are general UAE real estate, not specific to Emaar. The news about Emaar's ambitious masterplan is in recent_news and disclosures. Given the 4-week horizon and no clear imminent catalyst, and the negative price trend, a HOLD might be appropriate. Confidence: The evidence is mixed: strong fundamentals (growth, low leverage, high dividend) vs poor price momentum and technicals. No dated catalyst. So confidence likely 50-69 range ("clear evidence with real conflicts"). But note: if we output HOLD, target is null, confidence can be below 40? The instruction: "output HOLD below 40" means if confidence is below 40, we should output HOLD. But also HOLD can be output with higher confidence if evidence conflicts. Since there are conflicts, confidence could be around 60. But the rule: "confidence bands: ... 50-69 = clear evidence with real conflicts". So confidence in 50-69 fits a HOLD due to conflicts. So I'll set confidence 60. Target: null for HOLD. Point: a one sentence citing a figure. For example: "Despite strong revenue growth (2-year CAGR of 36.1% to AED 49.6bn in 2025) and a well-covered dividend (8.65% yield, 44.7% payout), net margin compressed from 55.4% in 2023 to 45.0% in 2025, and the stock's 13.2% decline over the past month underperforms the market." Risk: a one-liner. "Near-term downside risk from technical weakness and lack of imminent catalysts, while macro and project delays could dampen sentiment." Citations: need at least 2, but since it's HOLD, probably still need them. We'll cite: financial_statements annuual revenue growth (rev_cagr_2y_pct) and net margin trend or something. Also dividend yield or payout ratio. And maybe the recent price performance or technicals. But careful: The instructions say "non-HOLD stances need at least 2." So HOLD is allowed with fewer? It says "non-HOLD stances need at least 2." So HOLD can have 1 or 0? But we'll provide some anyway. We'll cite key fields. JSON keys: citations, point, risk, stance, confidence, target. citations: array of objects with field (dotted path) and value. We need exact paths as listed. Possible fields: - financial_statements.derived.rev_cagr_2y_pct value 36.1 - financial_statements.annual.0.net_margin_pct value 45.0 (2025) - financial_statements.annual.2.net_margin_pct value 55.4 (2023) - fundamentals.dividend_yield value 8.6505 - fundamentals.payout_ratio value 44.69 - indicators.ret_1m_pct value -13.2075 - etc. I'll pick 3 citations: rev growth, margin compression, and dividend yield or payout. Point: "Multi-year revenue grew at a 36.1% 2-year CAGR to AED 49.6bn, but net margin shrank from 55.4% (2023) to 45.0% (2025), reflecting sector-wide margin pressures even as dividends remain robust at an 8.65% yield with 44.7% payout." Risk: "Stock may face continued pressure due to negative momentum (RSI 33, -13.2% 1-month return) and no clear positive catalyst in the next four weeks." Stance: HOLD Confidence: 60 Target: null Make sure JSON is the only output.

We are asked to provide a TECHNICAL lens rating for EMAAR. The horizon is 4 weeks ending 2026-08-17. We need to output JSON with citations, point, risk, stance, confidence, and target. First, recall the instructions: We are the TECHNICAL lens. We must reason only over the evidence pack, citing exact figures. We need to weigh technicals: trend (MA50 vs MA200, price vs MA200), momentum, vol, drawdown/gap structure, relative strength vs DFMGI. If corporate_actions.upcoming_ex_date is present, treat the ex-date drop as mechanical, not a signal. But check: there is no upcoming ex-date in the pack; the most recent ex-date was 2026-04-03, which is in the past. So no ex-date mechanical drop in the horizon. Let's extract technical indicators: Spot price: 11.04 MA50: 11.8376 MA200: 12.7121 Price vs MA200: pct_vs_ma200: -13.1536 (so price is below MA200 by ~13%) MA50 vs MA200: Since MA50 (11.8376) is below MA200 (12.7121), that's a bearish crossover/trend. RSI14: 33.2144 (near oversold, but not yet at 30; bearish momentum) Momentum indicators: tv_technicals: - tv_recommend_all: -0.5576 (bearish) - tv_recommend_ma: -0.9333 (very bearish moving average signal) - tv_recommend_other: -0.1818 (mildly bearish) - CCI20: -190.5061 (deeply oversold, might indicate extreme weakness) - Stoch K: 14.1069 (oversold below 20) - Williams %R: -86.7647 (oversold) - ADX: 20.793 (below 25, so no strong trend) Volatility: realized_vol_annual_pct: 41.9849 (high), atr14_pct_of_price: 2.3292 (indicating significant daily ranges) Drawdown: max_drawdown_1y_pct: -37.7193, pct_off_20d_high: -14.4186 (so price is 14% below its 20-day high) Gap structure: largest_gap_3m_pct: 12.7778 (large gap, maybe event-driven), pct_no_trade_days_3m: 4.6875 (low, high trading activity) Relative strength vs DFMGI: rel_strength_3m_vs_dfmgi_pct: -7.9134 (underperforming the index) Returns: ret_1m_pct: -13.2075, ret_3m_pct: -2.7313, ret_12m_pct: -10.6863. Very weak recent performance, especially last month. Volume: rel_volume: 0.973 (average, not extreme) Liquidity: advv_30d_aed_m: 270.06 (decent) Note: There are no upcoming ex-dividend dates. The dividend history shows cash dividends, but the next ex-date likely isn't in the horizon. From a pure technical standpoint, the stock is in a downtrend: price below both MA50 and MA200, with MA50 below MA200 (death cross-like). Momentum oscillators are oversold, which could indicate potential for a bounce, but the overall trend is negative. Relative strength is negative. Within a 4-week horizon, technicals suggest continued pressure, possibly a short-term oversold bounce, but the overall trend is down. The confidence might be moderate. We can't rely on a specific catalyst, but we have a recent news about a mega-project, but that's not a dated catalyst inside the horizon with a specific date. So maybe confidence is lower, maybe around 50-69 because of clear evidence but conflicts (oversold but downtrend). But oversold alone is not a strong buy signal. The evidence pack has multiple technical figures confirming weakness. Now, we need to output a JSON with: - citations: list at least 2 for non-HOLD. We'll likely have a stance of SELL or HOLD? Given the technicals, SELL seems appropriate. But check confidence: if below 40, must be HOLD. We need to assign confidence based on the guidelines: 50-69 if clear evidence with real conflicts. Here, we have clear evidence of downtrend, but oversold conditions provide conflict. So confidence maybe 55? That's above 40, so we can have a stance. Or we could say HOLD with low confidence? The instructions: "output HOLD below 40". So if confidence is 50-69, we output stance with that confidence. We'll set confidence to 55. Stance: SELL, because trend is down, price below key MAs, negative momentum, underperformance. But we need to derive a target for 4-week horizon using pack evidence. Not restating analyst target. We could use technical levels: maybe support near 10.15 (52-week low). Price is 11.04, so target could be 10.15? But that's a 52-week low, which might act as support. But we need to project a 4-week target. Could use the MA200 as resistance: 12.71? That would be a bounce target if a reversal, but we are bearish. For a SELL stance, target would be lower. Maybe we can calculate a bearish target by assuming the distance from MA200 continues? Current price is 13.15% below MA200. If it drops further, perhaps to the lower end of the recent range. The 52-week low is 10.15. That's about 8% below current. We could set target as 10.15. But the horizon is 4 weeks, so maybe a gradual decline. Could also use ATR: ATR14% of price is 2.33%. So over 4 weeks (20 trading days), average move could be around 2.33% * sqrt(20) ~ 10.4% from volatility? But careful: that's not a target. Simpler: the stock is in a downtrend with -13% last month. Extrapolating linear? Not advisable. Better: the low of 10.15 is the strongest support. But if we are bearish, we might target that level. However, we must derive target from pack evidence. The high_52w and low_52w are in tv_technicals. So we could set target as 10.15. But is that justified? Possibly, as a downside target. Alternatively, we might not output a target if unsure, but instructions say if you output a target, derive it. We can output target as 10.15 (the 52-week low). But let's see: the stock is 11.04, 10.15 is about 8% drop. In 4 weeks, it's possible. That seems reasonable. Or we could say null if we don't have enough. But we can provide a target. I'll set target = 10.15. Point: one sentence citing a figure. For a SELL: "Price trades 13.15% below MA200 (12.71) with MA50 below MA200 and RSI14 at 33.21, indicating a sustained downtrend." That cites pct_vs_ma200, ma50, ma200, rsi14. Risk: one line. "Short-term oversold bounce possible but trend remains negative." Now, citations: we need at least 2. Cite exact dotted paths and values. For instance: - field: indicators.pct_vs_ma200, value: -13.1536 - field: indicators.rsi14, value: 33.2144 - field: indicators.ma50, value: 11.8376 - field: indicators.ma200, value: 12.7121 We'll pick two: pct_vs_ma200 and rsi14. Confidence: 55 (clear evidence with conflicts: oversold vs downtrend). Stance: SELL. Target: 10.15 (but need to verify that the 52-week low is in tv_technicals.low_52w: 10.15). So we can cite that? But our point and risk don't use it. We could cite low_52w as a target support level. But the target is our derived number. The instructions say: "if you output a target, derive it from pack evidence for the 4-week horizon". So we can derive from low_52w. So we could add a citation for target: field: tv_technicals.low_52w, value: 10.15. Or we could just use it without citing, but we'll cite it. But citations list should be the fields your case rests on. So we'll cite pct_vs_ma200, rsi14, and optionally low_52w if we use it for target. But we need at least 2 citations for non-HOLD. So two main ones will suffice. Now, we must ensure order of keys: citations, point, risk, stance, confidence, target. Point: "Price trades 13.15% below MA200 (12.71) with MA50 (11.84) below MA200, RSI14 at 33.21 signaling downward momentum." Risk: "Oversold indicators (Stoch K 14.11, Williams %R -86.76) could trigger a short-term bounce, but the primary trend remains bearish." Confidence: 55. Target: 10.15. Check confidence bands: 50-69 = clear evidence with real conflicts. Yes, we have oversold conflicting with downtrend. So 55 fits. Now, output JSON. Ensure no trailing commas, double quotes. Strings properly escaped. We'll format. Final output: { "citations": [ {"field": "indicators.pct_vs_ma200", "value": -13.1536}, {"field": "indicators.rsi14", "value": 33.2144} ], "point": "Price trades 13.15% below MA200 (12.71) with MA50 (11.84) below MA200, RSI14 at 33.21 signaling downward momentum.", "risk": "Oversold oscillators (Stoch K 14.11, Williams %R -86.76) could trigger a short-term bounce, but primary downtrend persists.", "stance": "SELL", "confidence": 55, "target": 10.15 } Make sure target is number, not string. I'll output only JSON.

We are asked to output a single JSON object with the VALUATION lens for EMAAR over a 4-week horizon ending 2026-08-17. The lens focuses on multiples vs fair value, dividend support, analyst consensus including drift. We need to reason over the evidence pack, cite exact figures, and decide stance (BUY/HOLD/SELL), confidence, point, risk, target. First, let's extract relevant data for valuation: - Fundamentals: pe_ttm = 5.1664, pb = 1.035, ps = 1.9194, dividend_yield = 8.6505, payout_ratio = 44.69, implied_upside_pct = 52.6268 (from analyst). - Peer context: median_pe_ttm = 11.32, median_pb = 1.35, median_div_yield = 4.55, pe_percentile = 7 (very low), div_yield_percentile = 97 (very high). - Consensus signal drift: forward_pe = 5.118, tv_recommend_all = -0.5576, target_mean_delta_10d_pct = -0.61, target_dispersion = 0.42. - Analyst: rec = strong_buy, target_mean = 16.85, eps_rev_30d_pct = 2.7597, eps_rev_90d_pct = -7.7528, net_up_30d = 1, rating_drift = -0.18. - Dividend history: 100% cash dividends for 2026 ex-date 2026-04-03, 2025 100%, 2024 50%, etc. So strong dividend. - Financial statements: strong profitability, net margin 45% (2025), roe 22.2%, OCF well above net income. - Technicals: price at 11.04, down 13.2% in 1 month, RSI 33.2 (almost oversold), below both MA50 and MA200, pct_vs_ma200 -13.15%. - Recent news: big masterplan AED200bn project to be unveiled (recent_disclosures: "Emaar Prepares to Unveil Its Most Ambitious Masterplan Ever" dated 2026-06-11), but also Creek Tower tender delay (2026-06-23). Valuation lens: The stock looks undervalued on multiples: P/E 5.17 vs peer median 11.32, P/B 1.035 vs peer 1.35, dividend yield 8.65% vs peer 4.55%. Analyst consensus is strong buy with target 16.85, implying 52.6% upside. However, the short-term technicals are bearish and analyst estimate revisions have 90-day negative drift (-7.75% EPS revisions) though recent 30-day positive (+2.76%). The consensus signal drift shows TV recommend -0.56 (bearish), but that might be technical-driven. Over a 4-week horizon, the valuation support and potential catalyst from the masterplan unveiling (though we don't know exact date; recent news says "prepares to unveil" but no dated catalyst within 4 weeks? The disclosure is from June 11, says "prepares to unveil", but no specific date. However, the horizon ends Aug 17, so if the unveiling happens in that period, it could be a catalyst. But we cannot assert a specific dated catalyst unless it appears. The news says "Emaar readies vast Dubai urban district" on June 12. There might be an event, but we don't have a clear date. So maybe no dated catalyst, so confidence cannot be 90-100. We'll weigh aligned figures. Point: Mention low P/E and high dividend yield relative to peers. Risk: Could be macro or project delays. Stance: BUY, given strong fundamentals and deep discount, but with caution due to technical weakness. Confidence: Multiple aligned figures, no dated catalyst, so 70-89 range. Let's pick 75. Target: Derive from evidence for 4-week horizon. We cannot use analyst target (12-month). We need to derive based on valuation multiples or reversion. Perhaps a target based on P/E multiple expansion to a conservative level. For example, if we assume P/E of 7 (still below peer median), that would give 7/5.1664 * 11.04 = about 14.95. But that's too high for 4 weeks? Actually, over 4 weeks, price might not fully re-rate. Alternatively, we could look at the recent decline and expect a bounce. No clear catalyst, but valuation support suggests limited downside. Maybe target is 12% upside? Let's calculate: if the stock reverts to its MA50 (11.84), that's about 7.2% upside. Or if it recovers some of the 1-month loss (-13.2%), maybe a 10% bounce to ~12.14. But we need a rationale from pack. Since we are valuation lens, we could compare to peer median P/B: peer median P/B 1.35, EMAAR P/B 1.035. If we assume convergence to 1.2x P/B, book value per share = equity/market cap? Actually, equity 107676.3 million AED, shares outstanding? Not directly given. But we can compute: market cap = 98.64 billion, so book value per share = 107.6763 / (market cap/price) = 107.6763 / (98.640/11.04) = 107.6763 / 8.935 ≈ 12.05? Wait, market cap is 98,640 million, so number of shares = market cap / price = 98640.23 / 11.04 ≈ 8934.8 million shares. Equity = 107,676.3 million, so book per share = 12.05. Current P/B = 11.04/12.05 = 0.916? But given P/B is 1.035, that suggests book per share = 11.04/1.035 = 10.67. There's a mismatch because market cap is in AED? Actually, market cap is given as 98640230683.0, which is 98.64 billion, spot price 11.04, so shares = 98.64B/11.04 = 8.935B shares. Equity is 107.6763B, so book per share = 12.05, P/B = 11.04/12.05 = 0.916, but the pack says pb = 1.035. Maybe the pack uses tangible book or something? Let's trust the pack's pb = 1.035. So we can't easily compute intrinsic value without more data. Perhaps use analyst target as a reference but not as our target. Since no clear derivation, maybe output target as null? But the instruction says: "If you output a target, derive it from pack evidence for the 4-week horizon — do not restate analyst.target_mean". So if we can't derive a confident target, output null. But a valuation lens often has a fair value estimate. Could we use a simple P/E expansion to peer median? That would be 11.32/5.1664 * 11.04 = 24.2, too high. More conservatively, target could be 12.0, which is near the 52-week low of 10.15 and seems like a support. Actually, from valuation, the stock is deeply undervalued, but 4-week horizon is short, so target might be a modest recovery. Given the technicals are weak, a target could be a reversion to the lower end of a range. Let's set target = null to be safe, as we don't have a clear valuation method that gives a precise 4-week target. But we need to output a target if possible. Maybe target based on dividend yield support: At current price, dividend yield 8.65%. If we assume the market requires a 7% yield, then price would be (dividend per share)/0.07. Need dividend per share: payout ratio 44.69%, EPS? From fundamentals, roe = 22.21%, pb = 1.035, so book per share = 10.67, equity per share = 10.67, EPS = ROE * book = 0.2221*10.67 = 2.37. Payout ratio 44.69% gives DPS = 1.06. That is consistent with dividend yield = 1.06/11.04 = 9.6%, but pack says 8.65% yield, maybe using trailing or different. Anyway, if DPS is 1.06, at 7% yield, price = 15.14. But that's long-term. For 4 weeks, no. Given the lack of a clear catalyst and the instruction not to fabricate, I'll set target = null. Now, confidence: Multiple aligned figures: pe_ttm (5.17) vs peer (11.32), dividend yield (8.65) vs peer (4.55), pb (1.035) vs peer (1.35). Also implied upside 52.6%, strong buy rec. But there are conflicts: negative 90d EPS revisions, technical bearishness. No dated catalyst. So confidence should be 70-89. I'll pick 75. Point: "Emaar trades at a P/E of 5.17x vs peer median 11.32x and offers an 8.65% dividend yield, yet the stock has declined 13.2% in the past month, presenting a deep-value opportunity." Risk: "Further delays in mega-projects and negative sentiment from technical breakdown could postpone re-rating." Stance: BUY. We need citations: at least 2 for non-HOLD. Cite fields with exact values. I'll cite pe_ttm, peer median_pe_ttm, dividend_yield, peer median_div_yield, implied_upside_pct, maybe consensus forward_pe. I'll pick: - {"field":"fundamentals.pe_ttm","value":5.1664} - {"field":"peer_context.median_pe_ttm","value":11.32} - {"field":"fundamentals.dividend_yield","value":8.6505} - {"field":"peer_context.median_div_yield","value":4.55} Also maybe analyst.implied_upside_pct: 52.6268. Now, output JSON. Remember order: citations, point, risk, stance, confidence, target. Target: null. Confidence: 75. That's it.